Data from Trovagene's Phase Ib/II clinical trial assessing onvansertib in patients with relapsed or refractory acute myeloid leukemia showed the drug was safe and effective, according to a presentation made at the 2019 European Society for Medical Oncology Conference. Trovagene plans to enroll 32 patients with AML in the midstage trial to evaluate onvansertib combined with decitabine in participants who complete at least a single treatment cycle.
Positive results reported by Trovagene on onvansertib midstage trial
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.